Projects
A single-cell approach to identify biomarkers of efficacy and toxicity for immune checkpoint blockade in non-small cell lung cancer. KU Leuven
Immunotherapy, and specifically immune checkpoint inhibition (ICI), has revolutionized care for lung cancer patients. Despite the undeniable progress, ICI has also brought along a whole new spectrum of side effects termed immune-related adverse events (irAEs). ICI-pneumonitis is an irAE of special interest; it has a high prevalence in anti-PD-1/PD-L1 treated lung cancer patients and is the most frequent fatal irAE in this population. This ...
Exploring the potential and underlying mechanisms of therapeutic activation of p53 in combination with immunotherapy to stimulate an innate immune response against non-small cell lung cancer. University of Antwerp
Leveraging patient-driven research to improve rational therapy selection in (ROS1+) non-small cell lung cancer. University of Antwerp
Exploring the potential and underlying mechanisms of therapeutic activation of p53 in combination with immunotherapy to stimulate an innate immune response against non-small cell lung cancer. University of Antwerp
Creation of a 3D CRiMe scene to unravel Cytotoxicity Resistant Mechanisms in non-small cell lung cancer. Vrije Universiteit Brussel
CTL-killing resistant mechanisms (CRMs) should be ...
Exploring the potential and underlying mechanisms of therapeutic activation of p53 in combination with immunotherapy to stimulate an innate immune response against non-small cell lung cancer. University of Antwerp
Charting non-small cell lung cancer evolution and heterogeneity through multi-omics analysis and deconvolution KU Leuven
n many malignancies, molecular and cellular heterogeneity poses major challenges for diagnosis and treatment. Tumours are composed of subpopulations of cells harbouring distinct genomic alterations (subclones) which can affect their phenotype. Studies of intra-tumour heterogeneity generally focus on a single information layer. However, multi-omics characterisation is required to shed light on the functional impact of subclonal mutations. ...
Defining the cDC-cellular interactome in non-small cell lung carcinoma to unleash their full potential for cancer immunotherapies Vrije Universiteit Brussel
Promotor: Damya Laoui
Diagnostic examinations of an autologous tumor-immune xenograft as a test platform for immunotherapeutic intervention with non-small cell lung cancer Ghent University
1. A systematic mapping of the dynamic interactions between growing tumors and the immune system, with a
dissection of molecular mechanisms leading to suppression/subversion of DCs and effector lymphocytes
particularly in lung cancer
2. Use this new knowledge to (i) manipulate DCs ex-vivo in order to create a vaccine resistant to the most
relevant in vivo suppressive signals, (ii) disrupt the immunosuppressive networks in ...